Dyne Therapeutics Inc — Cash Flow (NASDAQ:DYN) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Cash from operating activities 46.51 M119.56 M153.65 M188.16 M292.37 M 375.71 M Cash from investing activities 45.66 M137.89 M87.2 M83.31 M204.08 M 45.74 M Cash from financing activities 380.69 M157.82 M37.39 M54.32 M809.89 M 462.98 M Free cash flow 45.35 M115.94 M150.58 M187.43 M289.99 M 373.2 M

Notizie

Dyne Therapeutics earnings ahead: DMD filing timeline in focus

Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside?

Dyne Therapeutics: 2026 Catalysts Point To Further Upside (NASDAQ:DYN)

Il Giappone concede lo status di farmaco orfano al trattamento DM1 di Dyne

Japan grants orphan drug status to Dyne’s DM1 treatment

Dyne Therapeutics, Inc. (DYN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Dyne Therapeutics, Inc. (DYN) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:DYN) 2026-01-14

Dyne Therapeutics nomina Vikram Karnani nel consiglio di amministrazione

Dyne Therapeutics appoints Vikram Karnani to board of directors

Dyne Therapeutics raccoglie 402,5 milioni di dollari in un’offerta pubblica ampliata

Dyne Therapeutics raises $402.5 million in upsized public offering

Daktronics, Photronics, Dave & Buster's Entertainment, GE Vernova And Other Big Stocks Moving Higher On Wednesday - Abivax (NASDAQ:ABVX), Braze (NASDAQ:BRZE)